psmaddition: 177lu-psma-617 plus standard of care vs soc alone in patients with mhspc
Published 1 year ago • 151 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
11:49
lutetium-177 (pluvicto) vs. psma-actinium | #markscholzmd #alexscholz #pcri
-
22:27
prostate cancer treatment in germany - lutetium-177 psma | dr. med. stefan dresel | ask the doctor
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
3:17
safety and efficacy of 177lu-psma-617
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
4:48
vision: lu-177-psma-617 in mcrpc
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
11:39
psmafore trial & enzalutamide with 177lu-psma-617 for mcrpc | dr. dharmender malik | 05th knowledge